An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thromboythemia Myelofibrosis and Post Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50x109 /L to 100 x 109/L
What is the purpose of this trial?
- 18 Years and older
- Incyte Corporation
- January 2012
- Last Updated:
- Study HIC#:
Clinicaltrials.gov ID: Yale4011303